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Introduction
The direct thrombin inhibitor bivalirudin is thought to display various advantages in the treatment of acute coronary syndromes and during percutaneous coronary intervention as compared to unfractionated heparin. Thus, bivalirudin in contrast to heparin is able to inhibit fibrin-bound thrombin by displacing fibrin from its binding site (Bates and Weitz, 2000) . Furthermore, bivalirudin is not inhibited by platelet factor 4 which is released from activated platelets and binds with high affinity to heparin thereby abrogating its activity (Weitz and Crowther, 2002) . It has also been shown that bivalirudin in contrast to heparin does not lead to formation of platelet-monocyte (Harding, et al., 2006) and platelet-leukocyte aggregates (Keating, et al., 2006) .
The results of the ACUITY trial, a large scale clinical trial including patients with moderate to high risk acute coronary syndromes suggest that treatment with bivalirudin may indeed be superior to a regimen of heparin plus glycoprotein IIb/IIIa inhibitor (Stone, et al., 2007) . However, the advantages observed concerning the net clinical end point in this trial were not explained by a reduction in ischemic events but by reduced rates in major bleeding (Stone, et al., 2007) . In the REPLACE-2 trial which demonstrated that bivalirudin is not inferior to heparin plus glycoprotein IIb/IIIa inhibitor in patients undergoing urgent or elective percutaneous coronary intervention bivalirudin treatment again was shown to be accompanied with a lower rate of major bleeding but a trend towards an even higher rate of peri-procedural non-Q-waveinfarctions (Lincoff, et al., 2004) . A recently published study in high risk patients with ST-segment elevation myocardial infarction who were treated with heparin plus glycoprotein IIb/IIIa or bivalirudin alone for primary percutaneous coronary intervention revealed similar findings; the observed reduced net adverse clinical events were due to a lower rate of major bleeding but not to a reduction in ischemic event-in contrast an increased rate of stent thrombosis with bivalirudin was observed JPET #142414 in this trial (Stone, et al., 2008) . Thus, the theoretical pharmacokinetic and pharmacodynamic advantages of bivalirudin do not translate into a clinical reduction in ischemic events. This could easily be explained by the fact that bivalirudin was compared to the combination of heparin and glycoprotein IIb/IIIa inhibitor, instead of, for example, to heparin alone. However, it can also not be excluded from the results of these studies that extra-coagulant effects of bivalirudin as reported herein may contribute to this observation.
Reduced vascular nitric oxide bioavailability and concomitant endothelial dysfunction due to oxidative stress has often been linked to initiation and progression of acute and chronic coronary artery disease (Valgimigli, et al., 2003; Warkentin, 2004) . The beneficial clinical effects of several cardiovascular drugs -for example 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (John, et al., 1998; Laufs, et al., 1998) , ACE inhibitors (Mancini, et al., 1996) , clopidogrel (Heitzer, et al., 2006) , and AT1 receptor blockers (Sudano, et al., 2006) -have been in part attributed to their pleiotropic positive effects on increasing vascular NO-bioavailability via different mechanisms. In addition, our group has recently shown that unfractionated heparin acutely improves systemic NO-bioavailability as assessed by flow mediated dilation (Baldus, et al., 2006) . As a possible mechanism for this phenomenon we found that heparin electrostatically interacts with myeloperoxidase (MPO) -an enzyme which is abundantly expressed by polymorphonuclear neutrophils and has been shown to decrease endothelial NO-bioavailability (Eiserich, et al., 2002) -and thus mobilizes the enzyme from the vessel wall (Baldus, et al., 2006) .
The objective of the current study was to determine whether bivalirudin has also an impact on endothelial function in patients undergoing elective percutaneous coronary intervention and whether this impact might also be explained by electrostatic JPET #142414
Methods

Patients.
The study was conducted in accordance with the principles outlined in the declaration of Helsinki, was approved by the Ethics Committee of Hamburg, and all patients gave written informed consent prior to enrolment. Thirty consecutive patients, electively admitted to undergo elective percutaneous coronary intervention and diagnosed for lesions suitable for percutaneous coronary intervention were included into this double-blinded randomized trial using unfractionated heparin and bivalirudin, respectively. Patients with acute coronary syndromes within one month prior to study entry, congestive heart failure, impaired renal function (creatinine > 2.0 mg/dl) and intake of long-acting anti-anginal medication and oral anticoagulant drugs were excluded. After a 12 hour overnight fast, patients received either unfractionated heparin (70 U/kg) or bivalirudin (0.75 mg/kg) in a randomized fashion. Blood samples were taken from each subject before and 15 minutes after administration of the study medication and plasma was frozen at -80°C until further analysis. All patients underwent assessment of flow-mediated dilation of the brachial artery prior to and 15 minutes after administration of study medication. Thereafter patients were transferred into the catheterization laboratory. A research nurse not involved into the study unblinded the study arm and reassessed the activated clotting time. The percutaneous coronary intervention itself -executed by an independent operator -was performed by continuation of either heparin or bivalirudin, respectively according to current guidelines (Smith, Jr., et al., 2006) .
Vascular function testing.
Ultrasound determination of flow-mediated dilation (FMD) was performed as previously described (Rudolph, et al., 2007b) according to expert guidelines proposed by the International Brachial Artery Reactivity Task Force (Corretti, et al., 2002) . Briefly, a Siemens Sonoline G50 ultrasound system with 12
MHz linear array transducer was used to record 2D cine-sequences of the brachial JPET #142414 artery over 4 seconds at baseline and 1 minute after induction of reactive hyperemia by 5-minute cuff occlusion of the forearm. Mean flow velocity was assessed by pulsed wave Doppler with correction of insonation angle at baseline and peak hyperemic flow to calculate the flow ratio. Subjects were instructed not to eat, drink or smoke within 12 hours prior to testing. 2D sequences were analyzed using an edge detection software (Brachial Analyzer, Medical Imaging Applications LLC). The operators were blinded to patients´ treatment. in Supplemental Figure 2 . The limit of detection, defined as a signal-to-noise-ratio of 1:10 was 1 ng/ml, the limit of quantification, defined as a signal-to-noise-ratio of 1:3, was 3.3 ng/ml. A more detailed description of the ESI-LC-MS-analysis of bivalirudin can be found in the supplemental data.
Assessment
Binding of bivalirudin to BAEC. BAEC grown to confluence on 6-well plates were incubated with bivalirudin (0, 5, 10, 15 and 20 μg/ml) for 15 minutes at 4°C. BAEC were grown to confluence on 6-well plates and incubated with 50 nM MPO for 15 minutes at 37°C and co-incubated with either control, heparin (5 U/ml) or bivalirudin (15 μg/ml). Subsequently cells were washed, scraped in 1.2 ml of phosphate-buffered saline and transferred to the NO measuring chamber. 0.2 μl of NO solution was added to the cell lysate to a final concentration of 20 nM. H 2 O 2 (50 μmol/l) was injected once the response had stabilized. NO consumption was measured continuously with a NO-specific electrode (Free Radical Analyzer, World
Precision Instruments, Hertfordshire, United Kingdom). NO consumption per second was determined by using provided software (Apollo 4000).
Immunofluorescence. Confluent BAEC were incubated with MPO (13 nmol/l, 15 minutes at 37°C) and co-incubated with either control, heparin (5 U/ml) or bivalirudin (15 μg/ml). 
Results
Patients' characteristics. A total of 30 patients were included into the study.
Patients were randomly assigned to either receive bivalirudin or unfractionated heparin, respectively. As shown in Table 1 1A ).
Flow-mediated dilation (FMD).
Whereas heparin led to a significant increase in FMD, FMD decreased significantly after administration of bivalirudin (Fig. 1B) . These changes were also reflected by absolute changes in vessel diameter (heparin: observed in the supernatant ( Fig. 2A) , consistent with a 116% increase in fibronectinadherent MPO, as detected by western blot analysis (Fig. 2B) . In contrast, incubation with heparin significantly increased MPO activity in the supernatant and decreased fibronectin-adherent MPO. Similarly, co-incubation with MPO and bivalirudin on BAEC showed a decrease of MPO activity in the supernatant and an increase in celladherent MPO activity which was dependent on the dose of bivalirudin ( Fig. 2C and   2D ). Direct inhibition of MPO activity by bivalirudin was not observed (data not shown). group the carboxyterminal end of the peptide was confirmed by ESI-LC-MS (Supplemental Fig. 1D-1F ) and was shown to blunt binding of MPO (Fig. 4) .
Binding
NO consumption in vitro.
To evaluate whether bivalirudin-facilitated binding of MPO to BAEC translates into increased NO consumption in vitro, real-time continuous measurements of NO consumption were performed using a NO-specific electrode.
Co-incubation of BAEC with bivalirudin and MPO resulted in a significantly increased NO consumption compared to control and heparin in combination with MPO ( Figure   5A and 5B). 
Discussion
Herein we report that 1.) bivalirudin in opposition to heparin impairs flow-mediated dilation and decreases MPO levels in patients undergoing elective percutaneous coronary intervention 2.) bivalirudin avidly binds to endothelial cells and also binds to myeloperoxidase via its negatively charged carboxyterminal end 3.) bivalirudin reduces NO-bioavailability and increases formation of oxidized tyrosine residues by facilitation of MPO binding to endothelial cells.
Myeloperoxidase has traditionally been viewed as an enzyme of host defense, but has recently emerged as a potential participant in the promotion and propagation of acute and chronic cardiovascular disease (Baldus, et al., 2003; Brennan, et al., 2003; Rudolph, et al., 2007a; Eiserich, et al., 2002; Eiserich, et al., 1998 (Baldus, et al., 2001 ) and of importance, upon secretion from activated neutrophils, MPO binds to endothelial cells, undergoes transcytosis and accumulates in the sub-endothelial space, where it catalyzes the consumption of endothelial derived NO, thereby impairing vascular relaxation (Baldus, et al., 2001; Baldus, et al., 2002) .
MPO is known to have several heparin binding sites consisting of positively charged
Arginin-Lysin-residues which interact with the multiple anionic sulfate-residues of heparin and which physiologically bind to heparin/heparan-containing glycosaminoglycans on the surface of endothelial cells and thus enable its transcytosis to the sub-endothelial space (Baldus, et al., 2001 the effect of various heparin derivatives on reversing the vascular deposition of MPO and on the associated increase in vascular NO-bioavailability (Baldus, et al., 2006; Baldus, et al., 2001 ).
The 20 amino acid polypeptide bivalirudin is a direct thrombin inhibitor which binds to thrombin in a bivalent fashion. Whereas its aminoterminal end interacts with the active site of thrombin its carboxyterminal end interacts with exosite 1, a positive domain of thrombin which physiologically binds to fibrin (Warkentin, 2004 ). This interaction is explained by the fact that the carboxyterminal end of bivalirudin consists of a dodecapeptide with predominantly negatively charged amino acids. These multiple anionic amino acid side chains of the carboxyterminal dodecapeptidedomain of bivalirudin also suggested interactions with cationic amino acid residues of MPO (Eikelboom, et al., 2003; Weitz and Buller, 2002 ).
In the current study bivalirudin is found to interact with MPO by the interaction of the This article has not been copyedited and formatted. The final version may differ from this version. 
